SNPMiner Trials (Home Page)
Report for Clinical Trial NCT03622593
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered
at 8-week intervals or as specified in the protocol following treatment initiation, compared
with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).
The global enrollment phase has closed, but participants are still being recruited only at
sites in China.
Name: Aflibercept
Description: Aflibercept will be administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
Type: Drug
Group Labels: 1 C: Aflibercept Q8W
Name: Faricimab
Description: Faricimab will be administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or as specified in the protocol in arm B.
Type: Drug
Group Labels: 2 A: Faricimab Q8W B: Faricimab As Specified in Protocol
Name: Sham Procedure
Description: The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in all three treatments arms at applicable visits to maintain masking among treatment arms.
Type: Drug
Group Labels: 3 A: Faricimab Q8W B: Faricimab As Specified in Protocol C: Aflibercept Q8W
Primary Outcomes
Description: As measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters.
Measure: Average Change From Baseline in Best-Corrected Visual Acuity (BCVA) at 1 Year
Time: Baseline (Day 1) and 1 year
Secondary Outcomes
Measure: Percentage of Participants with a ≥2-Step Diabetic Retinopathy Severity (DRS) Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale (DRSS) at 1 Year Time: Baseline and 1 year
Measure: Change From Baseline in BCVA Over Time Time: From Baseline up to 2 years
Measure: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline Over Time Time: From Baseline up to 2 years
Measure: Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline Over Time Time: From Baseline up to 2 years
Measure: Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline Over Time Time: From Baseline up to 2 years
Measure: Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline Over Time Time: From Baseline up to 2 years
Measure: Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline Over Time Time: From Baseline up to 2 years
Measure: Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline Over Time Time: From Baseline up to 2 years
Measure: Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline Over Time Time: From Baseline up to 2 years
Measure: Percentage of Participants Avoiding a Loss of >0 Letters in BCVA From Baseline Over Time Time: From Baseline up to 2 years
Measure: Percentage of Participants Gaining ≥15 Letters or Achieving BCVA of ≥84 Letters Over Time Time: Up to 2 years
Measure: Percentage of Participants with BCVA Snellen Equivalent of 20/40 or Better Over Time Time: Up to 2 years
Measure: Percentage of Participants with BCVA Snellen Equivalent of 20/200 or Worse Over Time Time: Up to 2 years
Measure: Percentage of Participants with a ≥2-Step DRS Improvement From Baseline on the ETDRS DRSS Over Time Time: From Baseline up to 2 years
Measure: Percentage of Participants with a ≥3-Step DRS Improvement From Baseline on the ETDRS DRSS Over Time Time: From Baseline up to 2 years
Measure: Percentage of Participants Who Develop New Proliferative Diabetic Retinopathy Over Time Time: Up to 2 years
Measure: Percentage of Participants in the Faricimab As Specified in Protocol Arm on a Q4W, Q8W, Q12W, or Q16W Treatment Interval at 1 Year Time: 1 year
Measure: Percentage of Participants in the Faricimab As Specified in Protocol Arm on a Q4W, Q8W, Q12W, or Q16W Treatment Interval at 2 Years Time: 2 years
Measure: Change From Baseline in Central Subfield Thickness Over Time Time: From Baseline up to 2 years
Measure: Change From Baseline in Central Subfield Thickness at 1 Year Time: Baseline and 1 year
Measure: Percentage of Participants with Absence of DME Over Time Time: Up to 2 years
Measure: Percentage of Participants with Absence of Intraretinal Fluid Over Time Time: Up to 2 years
Measure: Percentage of Participants with Absence of Subretinal Fluid Over Time Time: Up to 2 years
Measure: Percentage of Participants with Absence of Intraretinal Fluid and Subretinal Fluid Over Time Time: Up to 2 years
Measure: Change From Baseline in National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Composite Score Over Time Time: From Baseline up to 2 years
Measure: Percentage of Participants with At Least One Ocular Adverse Event Time: Up to 2 years
Measure: Percentage of Participants with At Least One Non-Ocular Adverse Event Time: Up to 2 years
Measure: Plasma Concentration of Faricimab Over Time Time: Pre-dose on Day 1; Weeks 4, 28, 52, 76, and 100; and at Early Termination Visit (up to 2 years)
Measure: Percentage of Participants with Presence of Anti-Drug Antibodies Time: Pre-dose on Day 1; Weeks 4, 28, 52, 76, and 100; and at Early Termination Visit (up to 2 years)
Purpose: Treatment
Allocation: Randomized
Parallel Assignment
There are 2 SNPs
SNPs
1 Q12W
Percentage of Participants in the Faricimab As Specified in Protocol Arm on a Q4W, Q8W, Q12W, or Q16W Treatment Interval at 1 Year. --- Q12W ---
Percentage of Participants in the Faricimab As Specified in Protocol Arm on a Q4W, Q8W, Q12W, or Q16W Treatment Interval at 2 Years. --- Q12W ---
2 Q16W
Percentage of Participants in the Faricimab As Specified in Protocol Arm on a Q4W, Q8W, Q12W, or Q16W Treatment Interval at 1 Year. --- Q12W --- --- Q16W ---
Percentage of Participants in the Faricimab As Specified in Protocol Arm on a Q4W, Q8W, Q12W, or Q16W Treatment Interval at 2 Years. --- Q12W --- --- Q16W ---
HPO Nodes
HPO: Protein Mutations 0
SNP 0
Protein Mutations 0
SNP 0